Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 5/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
| ▸ | TDP2 | O95551 | 1/20 | 0.39 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22314549 | 0.84 | CA12 (0.44) | CA12CA9NOTUMSCN5AGRIN1 | |
| SCHEMBL22314897 | 0.84 | CA12 (0.44) | CA12CA9NOTUMSCN5AMAP4K1 | |
| SCHEMBL25865023 | 0.82 | CA12 (0.42) | CA12CA9NOTUMSCN5AGRIN1 | |
| SCHEMBL22314476 | 0.82 | CA12 (0.44) | CA12CA9NOTUMSCN5AGRIN1 | |
| SCHEMBL22314900 | 0.81 | MEN1 (0.45) | CA12CA9NOTUMSCN5ACYP11B2 | |
| SCHEMBL22314481 | 0.79 | SCN5A (0.43) | CA12CA9SCN5AGRIN1GRIN2B | |
| SCHEMBL22314913 | 0.78 | SCN5A (0.48) | CA12CA9SCN5AGRIN1GRIN2B | |
| SCHEMBL22314553 | 0.78 | TNIK (0.51) | CA12CA9GRIN1GRIN2BTNIK | |
| SCHEMBL14480871 | 0.76 | NOTUM (0.42) | CA12CA9NOTUMSCN5ACYP11B2 | |
| SCHEMBL22314943 | 0.74 | NOTUM (0.49) | CA12CA9NOTUMSCN5ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PREC MEDICINES INC (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PREC MEDICINES INC (US) | 2023-07-13 | — | — | US | disclosed |
| US-20200247793-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247793-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | CA12 1391/4885CA9 1572/4885NOTUM 1669/4885 |
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | CA12 1391/4885CA9 1572/4885NOTUM 1669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.